Asymptomatic/pauci-symptomatic creatine kinase elevations (hyperckemia)

Muscle and Nerve

Volumn 47, Issue 6, 2013, Pages 805-815

  Silvestri, Nicholas J ^a   Wolfe, Gil I ^a  

^a UNIVERSITY AT BUFFALO   (United States)

Author keywords

Asymptomatic; CK; Creatine kinase; HyperCKemia; Muscle; Myopathy

Indexed keywords

ALCOHOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CLOZAPINE; COCAINE; CREATINE KINASE BB; CREATINE KINASE MB; CREATINE KINASE MM; CYCLOSPORIN; DIAMORPHINE; FIBRIC ACID DERIVATIVE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; ISOTRETINOIN; PYRROLE DERIVATIVE;

ABNORMALLY HIGH SUBSTRATE CONCENTRATION IN BLOOD; ARTICLE; ASYMPTOMATIC DISEASE; CREATINE KINASE BLOOD LEVEL; ENZYME ASSAY; ENZYME MECHANISM; EXERCISE TOLERANCE; FATIGUE; HUMAN; HYPERCKEMIA; HYPERLIPIDEMIA; MUSCLE BIOPSY; MUSCLE CRAMP; MUSCLE WEAKNESS; MYALGIA; MYOPATHY; NEUROMUSCULAR DISEASE; PRIORITY JOURNAL; RHABDOMYOLYSIS; SYMPTOMATOLOGY;

ASYMPTOMATIC DISEASES; CREATINE KINASE; DIAGNOSIS, DIFFERENTIAL; HUMANS; METABOLIC DISEASES; MUSCULAR DISEASES; REFERENCE VALUES;

EID: 84878351629     PISSN: 0148639X     EISSN: 10974598     Source Type: Journal    
DOI: 10.1002/mus.23755     Document Type: Article

References (83)

1. Nanji AA. Serum creatine kinase isoenzymes: a review. Muscle Nerve 1983;6:83-90.
2. Kodatsch I, Finsterer J, Stollberger C. Serum creatine kinase elevation in a medical department. Acta Med Aust 2001;28:11-15.
3. Wong ET, Cobb C, Umehara MK, Wolff GA, Haywood LJ, Greenberg T, et al. Heterogeneity of serum creatine kinase activity among racial and gender groups of the population. Am J Clin Pathol 1983;79:582-586.
4. Brewster LM, Mairuhu G, Sturk A, van Montfrans GA. Distribution of creatine kinase in the general population: implications for statin therapy. Am Heart J 2007;154:655-661.
5. Scheurbrandt G, Mortier W. Voluntary newborn screening for Duchenne muscular dystrophy: a nationwide pilot program in West Germany. In: Serratrice G, Cros D, Desnuelle C, et al., editors. Neuromuscular diseases. New York: Raven Press; 1984. p 33-35.
6. Nardin RA, Zarrin AR, Horowitz GL, Tarulli AW. Effect of newly proposed CK reference limits on neuromuscular disorders. Muscle Nerve 2009;39:494-497.
7. Kyriakides T, Angelini C, Schaefer J, Sacconi S, Siciliano G, Vilchez JJ, et al. EFNS guidelines on the diagnostic approach to pauci- or asymptomatic hyperCKemia. Eur J Neurol 2010;17:767-773.
8. Chahin N, Sorenson EJ. Serum creatine kinase levels in spinobulbar muscular atrophy and amyotrophic lateral sclerosis. Muscle Nerve 2009;40:126-129.
9. Morandi L, Angelini C, Prelle A, Pini A, Grassi B, Bernardi G, et al. High plasma creatine kinase: a review of the literature and proposal for a diagnostic algorithm. Neurol Sci 2006;27:303-311.
10. Beyer IW, Karmali R, Demeester-Mirkine N, Cogan E, Fuss MJ. Serum creatine kinase levels in overt and subclinical hypothyroidism. Thyroid 1998;8:1028-1031.
11. Scott KR, Simmons Z, Boyer PJ. Hypothyroid myopathy with strikingly elevated serum creatine kinase level. Muscle Nerve 2002;26:141-144.
12. Duyff RF, van den Bosch J, Laman DM, van Loon BJ, Linssen WH. Neuromuscular findings in thyroid dysfunction: a prospective clinical and electrodiagnostic study. J Neurol Neurosurg Psychiatry 2000;68:750-755.
13. Kozanoglu E, Basaian S, Goucu MK. Proximal myopathy as an unusual presenting feature of celiac disease. Clin Rheumatol 2005;24:76-78.
14. Konikoff F, Halevy J, Theodor E. Serum kinase after intramuscular injections. Postgrad Med J 1985;61:595-598.
15. Montero Perez FJ, Munoz Avila J, Berlango Jimenez A, Duran Serantes M, Calderon de la Barca Vazquez JM, Jimenez Murillo L, et al. Increase of blood levels of creatine kinase following intramuscular injection. Med Clin 1996;107:649-654.
16. Chrissian SA, Stolov WC, Hongladarom T. Needle electromyography: its effects on serum creatine phosphokinase activity. Arch Phys Med Rehabil 1976;57:114-119.
17. Pedinoff S, Sandhu RS. Electromyography effect on serum creatine phosphokinase in normal individuals. Arch Phys Med Rehabil 1978;59:27-29.
18. Levin R, Pascuzzi RM, Bruns DE, Boyd JC, Toly TM, Phillips LH. The time course of creatine kinase elevation following concentric needle EMG. Muscle Nerve 1987;10:242-245.
19. Finsterer J, Mittendorfer B, Neuhuber W, Loscher WN. Influence of disposable, concentric needle electrodes on muscle enzyme and lactate levels. J Electromyogr Kinesiol 2002;12:329-337.
20. Miller JAL. Statins-challenges and provocations. Curr Opin Neuol 2005;18:494-496.
21. Thompson PD, Clarkson P, Karas RH. Statin-associated myopathy. JAMA 2003;289:1681-1690.
22. Vladutiu GI, Simmons Z, Isackson PJ, Tarnopolsky M, Peltier WL, Barboi AC, et al. Genetic risk factors associated with lipid-lowering drug-induced myopathies. Muscle Nerve 2006;34:153-162.
23. Kashani A, Phillips CO, Foody JM, Wang Y, Mangalmurti S, Ko DT, et al. Risks associated with statin therapy: a systematic overview of randomized clinical trials. Circulation 2006;114:2788-2797.
24. Chan J, Hui RL, Levin E. Differential association between statin exposure and elevated levels of creatine kinase. Am Pharmacother 2005;39:1611-1616.
25. Tomaszewski M, Stepien KM, Tomaszewska J, Czuczwar SJ. Statin-induced myopathies. Pharm Rep 2011;63:859-866.
26. Scelsa SN, Simpson DM, McQuistion HL, Ault K, Reichler B. Clozapine-induced myotoxicity in patients with chronic psychotic disorders. Neurology 1996;47:1518-1523.
27. Imai Y, Watanabe N, Hashimoto J, Nishiyama A, Sakuma H, Sekino H, et al. Muscle cramps and elevated serum creatine phosphokinase levels induced by beta-adrenoreceptor blockers. Eur J Clin Pharmacol 1995;48:29-34.
28. Imataka K, Seki A, Takahashi N, Fujii J. Elevation of serum creatine phosphokinase during pindolol treatment. Tohoku J Exp Med 1981;133:363-364.
29. Itoh H, Jingu Y, Numakami K, Saruta T. Effects of beta-blocking agents on the release of various enzymes in muscular tissues. Kitasato Arch Exp Med 1993;65(suppl):57-63.
30. Saruta T, Suzuki H, Kawamura M, Itoh H. Serum creatine phosphokinase levels during treatment with beta-adrenoreceptor blocking agents. J Cardiovasc Pharmacol 1985;7:805-808.
31. Goulden V, Layton AM, Cunliffe WJ. Long term saftey of isotretinoin as a treatment for acne vulgaris. Br J Dermatol 1994;131:360-363.
32. Guttman-Yassky E, Hayek T, Muchnik L, Bergman R. Acute rhabdomyolysis and myoglobinuria associated with isotretinoin treatment. Int J Dermatol 2003;42:499-500.
33. Landau M, Mesterman R, Ophir J, Mevorah B, Alcalay J, Harel A, et al. Clinical significance of markedly elevated serum creatine kinase levels in patients with acne on isotretinoin. Acta Derm Venereol 2001;81:350-352.
34. Hagberg M, Michaelson G, Ortelius A. Serum creatine kinase as an indicator of local muscular strain in experimental and occupational work. Int Arch Occup Environ Health 1982;50:377-386.
35. Clarkson PM, Nosaka K, Braun B. Muscle function after exercise-induced muscle damage and rapid adaptation. Med Sci Sports Exerc 1992;24:512-520.
36. Ehlers GG, Ball TE, Liston L. Creatine kinase levels are elevated during 2-a-day practices in collegiate football players. J Athlet Train 2002;37:151-156.
37. Kenney K, Landau ME, Gonzalez RS, Hundertmark J, O'Brien K, Campbell WW. Serum creatine kinase after exercise: drawing the line between physiological response and exertional rhabdomyolysis. Muscle Nerve 2012;45:356-362.
38. Kleppe B, Reimers CD, Altmann C, Pongratz DE. Findings in 100 patients with idiopathic increase in serum creatine kinase activity. Med Klin 1995;90:623-627.
39. Galarraga B, Sinclair D, Fahie-Wilson MN, McCrae FC, Hull RG, Ledingham JM. A rare but important cause for a raised serum creatine kinase concentration: two case reports and a literature review. Rheumatology 2002;42:186-188.
40. Lee KN, Csako G, Bernhardt P, Elin RJ. Relevance of macro creatine kinase type 1 and type 2 isoenzymes to laboratory and clinical data. Clin Chem 1994;40:1278-1283.
41. Schifferli JA, Despont JP, Cruchaud A, Carpentier N, Jeannet M, Schmidt M. Macro-creatine kinase type 1. Immunological studies in 14 patients with comments on clinical significance. Arch Pathol Lab Med 1986;110:425-429.
42. Comi GP, Prelle A, Bresolin N, Moggio M, Bardoni A, Gallanti Al, et al. Clinical variability in Becker muscular dystrophy genetic, biochemical and immunohistochemical correlates. Brain 1994;117:1-14.
43. Dabby R, Sadeh M, Herman O, Berger E, Watemberg N, Hayek S, et al. Asymptomatic or minimally symptomatic hyperCKemia: histopathologic correlates. Isr Med Assoc J 2006;8:110-113.
44. Morrone A, Zammarchi E, Scacheri PC, Donati MA, Hoop RC, Servidei S, et al. Asymptomatic dystrophinopathy. Am J Med Genet 1997;69:261-267.
45. Ferreiro V, Giliberto F, Noelia Muniz GM, Francipane L, Marzese DM, Mampel A, et al. Asymptomatic Becker muscular dystrophy in a family with a multiexon deletion. Muscle Nerve 2009;39:239-243.
46. Melis MA, Cau M, Muntoni F, Mateddu A, Galanello R, Boccone L, et al. Elevation of serum creatine kinase as the only manifestation of an intragenic deletion of the dystrophin gene in three unrelated families. Eur J Paediatr Neurol 1998;2:255-261.
47. Frydman M, Straussberg R, Shomrat R, Goebel H, Legum C, Shiloh Y. Duchenne muscular dystrophy and idiopathic hyperCKemia segregating in a family. Am J Med Genet 1995;58:209-212.
48. Griggs RC, Mendell JR, Brooke MH, Fenichel GM, Miller JP, Province M., et al. Clinical investigation in Duchenne dystrophy: V. Use of creatine kinase and pyruvate kinase in carrier detection. Muscle Nerve 1985;8:60-67.
49. Tachi N, Wakai S, Yutoh Y, Chiba S. Asymptomatic hyperCKemia: detection of an isolated carrier of Duchenne muscular dystrophy. J Child Neurol 1990;5:351-353.
50. Alias L, Gallano P, Moreno D, Pujol R, Martinez-Matos JA, Baiget M, et al. A novel mutation in the caveolin-3 gene causing familial isolated hyperCKaemia. Neuromuscul Disord 2004;14:321-324.
51. Carbone I, Bruno C, Sotgia F, Bado M, Broda P, Masetti E, et al. Mutation in the CAV3 gene causes partial caveolin-3 deficiency and hyperCKemia. Neurology 2000;54:1373-1376.
52. Fernandez C, Maues de Paula A, Figarella-Branger D, Krahn M, Giorgi R, et al. Diagnostic evaluation of clinically normal subjects with chronic hyperCKemia. Neurology 2006;66:1585-1587.
53. Merlini L, Carbone I, Capanni C, Sabatelli P, Tortorelli S, Sotgia F, et al. Familial isolated hyperCKaemia associated with a new mutation in the caveolin-3 (CAV-3) gene. J Neurol Neurosurg Psychiatry 2002;73:65-67.
54. Reijneveld JC, Ginjaar IB, Frankhuizen WS, Notermans NC. CAV3 gene mutation analysis in patients with idiopathic hyper-CK-emia. Muscle Nerve 2006;34:656-658.
55. Angelini C, Fanin M, Menegazzo E, Pia Freda M, Duggan DJ, Hoffman EP. Homozygous alpha-sarcoglycan mutation in two siblings: one asymptomatic and one steroid-responsive mild limb-girdle muscular dystrophy patient. Muscle Nerve 1998;21:769-775.
56. Fanin M, Pegoraro E, Matsuda-Asada C, Brown RH, Angelini C. Calpain-3 and dysferlin protein screening in patients with limb-girdle dystrophy and myopathy. Neurology 2001;56:660-665.
57. Hanisch F, Muller CR, Grimm D, Xue L, Traufeller K, Merkenschlager A, et al. Frequency of calpain-3 c.550delA mutation in limb girdle muscular dystrophy type 2 and isolated hyperCKemia in German patients. Clin Neuropathol 2007;26:157-163.
58. Galassi G, Rowland LP, Hays AP, Hopkins LC, DiMauro S. High levels of creatine kinase: asymptomatic prelude to distal myopathy. Muscle Nerve 1987;10:346-350.
59. Nguyen K, Bassez G, Krahn M, Bernard R, Laforet P, Labelle V, et al. Phenotypic study in 40 patients with dysferlin gene mutations: high frequency of atypical phenotypes. Arch Neurol 2007;64:1176-1182.
60. Prelle A, Tancredi L, Sciacco M, Chiveri L, Comi GP, Battistel A, et al. Retrospective study of a large population of patients with asymptomatic or minimially symptomatic raised serum creatine kinase levels. J Neurol 2002;249:305-311.
61. dePaula F, Vieira N, Starling A, Uraco Yamamoto L, Lima B, deCassia Pavanello R, et al. Asymptomatic carriers for homozygous novel mutations in the FKRP gene: the other end of the spectrum. Eur J Hum Genet 2003;11:923-930.
62. Penttila S, Palmio J, Suominen T, Raheem O, Evila A, Muelas Gomez N, et al. Eight new mutations and the expanding phenotype variability in muscular dystrophy caused by ANO5. Neurology 2012;78:897-903.
63. Schessl J, Kress W, Schoser B. Novel ANO5 mutations causing hyper-CK-emia, limb girdle muscular weakness and Miyoshi type of muscular dystrophy. Muscle Nerve 2012;45:740-742.
64. Merlini L, Sabatelli P, Columbaro M, Bonifazi E, Pisani V, Massa R, et al. Hyper-CK-emia as the sole manifestation of myotonic dystrophy type 2. Muscle Nerve 2005;31:764-767.
65. Bruno C, Bertini E, Santorelli FM, DiMauro S. HyperCKemia as the only sign of McArdle's disease in a child. J Child Neurol 2000;15:137-138.
66. Joy JL, Oh SJ. Asymptomatic hyper-CK-emia: an electrophysiologic and histopathologic study. Muscle Nerve 1989;12:206-209.
67. Filosto M, Tonin P, Vattemi G, Bertolasi L, Simonati A, Rizzuto N, et al. The role of muscle biopsy in investigating isolated muscle pain. Neurology 2007;68:181-186.
68. Simmons Z, Peterlin BL, Boyer PJ, Towfighi J. Muscle biopsy in the evaluation of patients with modestly elevated creatine kinase levels. Muscle Nerve 2003;27:242-244.
69. Brewster LM, de Visser M. Persistent hyperCKemia: fourteen patients studied in retrospect. Acta Neurol Scand 1988;77:60-63.
70. Malandrini A, Orrico A, Guadiano C, Gambelli S, Galli L, Berti G, et al. Muscle biopsy and in vitro contracture tests in subjects with idiopathic hyperCKemia. Anesthesiology 2008;109:625-628.
71. Rowland LP, Willner J, DiMauro S, Miranda A. Approaches to the membrane theory of Duchenne muscular dystrophy. In: Angelini C, Danieli GA, Fontarni D, editors. Muscular dystrophy-advances and new trends. Amsterdam: Excerpta Medica; 1980. p 3-13.
72. Afifi AK. Idiopathic hyperCKemia revisited. J Child Neurol 1998;13:251-252.
73. Capasso M, DeAngelis MV, DiMuzio A, Scarciolla O, Pace M, Stuppia L, et al. Familial idiopathic hyper-CK-emia: an underrecognized condition. Muscle Nerve 2006;33:760-765.
74. Lilleng H, Abeler K, Johnsen SH, Stensland E, Loseth S, Jorde R, et al. Variation of serum creatine kinase (CK) levels and prevalence of persistent hyperCKemia in a Norwegian normal population. The Tromso study. Neuromuscul Disord 2011;21:494-500.
75. D'Adda E, Sciacco M, Fruguglietti ME, Crugnola V, Lucchini V, Martinelli-Boneschi F, et al. Follow-up of a large population of asymptomatic/oligosymptomatic hyperCKemic subjects. J Neurol 2006;253:1399-1403.
76. Reijneveld JC, Notermans NC, Linssen WHJP, Wokke JHJ. Benign prognosis in idiopathic hyper-CK-emia. Muscle Nerve 2000;23:575-579.
77. Sunohara N, Takagi A, Nonaka I, Sugita H, Satoyoshi E. Idiopathic hyperCKemia. Neurology 1984;34:544-547.
78. Weglinski MR, Wedel DJ, Engel AW. Malignant hyperthermia testing in patients with persistently increased serum creatine kinase levels. Anesth Analg 1997;84:1038-1041.
79. Amaranath L, Lavin TJ, Trusso RA, Boutros AR. Evaluation of creatinine (sic) phosphokinase screening as a predictor of malignant hyperthermia. Br J Anaesth 1983;55:531-533.
80. Paasuke RT, Brownell AKW. Serum creatine kinase level as a screening test for susceptibility to maligant hyperthermia. JAMA 1986;255:769-771.
81. Ellis FR, Clarke IM, Modgill M, Currie S, Harriman DG. Evaluation of creatine phosphokinase in screening patients for malignant hyperthermia. BMJ 1975;3:511-513.
82. McPherson E, Taylor CA. The genetics of malignant hyperthermia: evidence for heterogeneity. Am J Med Genet 1982;11:273-285.
83. Britt BA, Endrenyi L, Peters PL, Kwong FH, Kadijevic L. Screening of malignant hyperthermia susceptible families by creatine phosphokinase measurement and other clinical investigations. Can Anaesth Soc 1976;23:263-284.